Jul 16, 2026
Serum Institute of India to Manufacture Experimental TB Vaccine M72/AS01E in Partnership with Gates Medical Research Institute
The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.
3 sources
00